Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.

Autor: De Giorgi, Ugo1 (AUTHOR) ugo.degiorgi@irst.emr.it, Hussain, Maha2 (AUTHOR), Shore, Neal3 (AUTHOR), Fizazi, Karim4 (AUTHOR), Tombal, Bertrand5 (AUTHOR), Penson, David6 (AUTHOR), Saad, Fred7 (AUTHOR), Efstathiou, Eleni8 (AUTHOR), Madziarska, Katarzyna9 (AUTHOR), Steinberg, Joyce10 (AUTHOR), Sugg, Jennifer10 (AUTHOR), Lin, Xun11 (AUTHOR), Shen, Qi12 (AUTHOR), Sternberg, Cora N.1,13 (AUTHOR) cns9006@med.cornell.edu
Zdroj: European Journal of Cancer. Dec2021, Vol. 159, p237-246. 10p.
Databáze: Academic Search Ultimate
Externí odkaz: